Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2007 3
2008 2
2009 5
2010 2
2011 1
2012 9
2013 11
2014 11
2015 6
2016 7
2017 8
2018 8
2019 15
2020 4
2021 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients.
Fabbiani M, Masini M, Rossetti B, Ciccullo A, Borghi V, Lagi F, Capetti A, Colafigli M, Panza F, Baldin G, Mussini C, Sterrantino G, Farinacci D, Montagnani F, Tumbarello M, Di Giambenedetto S. Fabbiani M, et al. Among authors: colafigli m. Viruses. 2023 May 8;15(5):1123. doi: 10.3390/v15051123. Viruses. 2023. PMID: 37243208 Free PMC article.
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M).
Di Giambenedetto S, Fabbiani M, Quiros Roldan E, Latini A, D'Ettorre G, Antinori A, Castagna A, Orofino G, Francisci D, Chinello P, Madeddu G, Grima P, Rusconi S, Di Pietro M, Mondi A, Ciccarelli N, Borghetti A, Focà E, Colafigli M, De Luca A, Cauda R; Atlas-M Study Group. Di Giambenedetto S, et al. Among authors: colafigli m. J Antimicrob Chemother. 2017 Apr 1;72(4):1163-1171. doi: 10.1093/jac/dkw557. J Antimicrob Chemother. 2017. PMID: 28093483 Clinical Trial.
Tonsillar Kaposi sarcoma in an HIV-negative patient.
Latini A, Alei L, Covello R, Cristaudo A, Colafigli M, Donà MG, Orsini D, Morrone A, Pellini R, Pichi B. Latini A, et al. Among authors: colafigli m. AIDS. 2019 Jun 1;33(7):1263-1264. doi: 10.1097/QAD.0000000000002202. AIDS. 2019. PMID: 31045945 No abstract available.
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial.
Fabbiani M, Di Giambenedetto S, Quiros-Roldan E, Latini A, Vullo V, Antinori A, Castagna A, Orofino G, Francisci D, Grilli E, Madeddu G, Grima P, Rusconi S, Del Pin B, Mondi A, Borghetti A, Focà E, Colafigli M, De Luca A, Cauda R. Fabbiani M, et al. Among authors: colafigli m. J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19808. doi: 10.7448/IAS.17.4.19808. eCollection 2014. J Int AIDS Soc. 2014. PMID: 25397552 Free PMC article.
HIV MDR is still a relevant issue despite its dramatic drop over the years.
Armenia D, Di Carlo D, Flandre P, Bouba Y, Borghi V, Forbici F, Bertoli A, Gori C, Fabeni L, Gennari W, Pinnetti C, Mondi A, Cicalini S, Gagliardini R, Vergori A, Bellagamba R, Malagnino V, Montella F, Colafigli M, Latini A, Marocco R, Licthner M, Andreoni M, Mussini C, Ceccherini-Silberstein F, Antinori A, Perno CF, Santoro MM. Armenia D, et al. Among authors: colafigli m. J Antimicrob Chemother. 2020 May 1;75(5):1301-1310. doi: 10.1093/jac/dkz554. J Antimicrob Chemother. 2020. PMID: 31976521
Overall Tolerability of Integrase Inhibitors in Clinical Practice: Results from a Multicenter Italian Cohort.
Ciccullo A, Baldin G, Borghi V, Sterrantino G, Madeddu G, Latini A, d'Ettorre G, Lanari A, Mazzitelli M, Colafigli M, Capetti AF, Oreni L, Lagi F, Rusconi S, Di Giambenedetto S. Ciccullo A, et al. Among authors: colafigli m. AIDS Res Hum Retroviruses. 2021 Jan;37(1):4-10. doi: 10.1089/AID.2020.0078. Epub 2020 Nov 2. AIDS Res Hum Retroviruses. 2021. PMID: 32998526 Free article.
Interpretation systems for genotypic drug resistance of HIV-1.
De Luca A, Antinori A, Di Giambenedetto S, Cingolani A, Colafigli M, Perno CF, Cauda R. De Luca A, et al. Among authors: colafigli m. Scand J Infect Dis Suppl. 2003;106:29-34. doi: 10.1080/03008870310009623. Scand J Infect Dis Suppl. 2003. PMID: 15000579 Review.
Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE).
Ciccullo A, Baldin G, Capetti A, Borghi V, Sterrantino G, Latini A, Madeddu G, Celani L, Vignale F, Rossetti B, Dusina A, Cossu MV, Restelli S, Gennari W, Lagi F, Giacomelli A, Colafigli M, Brescini L, Borghetti A, Mussini C, Rusconi S, Di Giambenedetto S. Ciccullo A, et al. Among authors: colafigli m. BMJ Open. 2019 Dec 2;9(12):e029960. doi: 10.1136/bmjopen-2019-029960. BMJ Open. 2019. PMID: 31796476 Free PMC article.
Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort.
Fabbiani M, Rossetti B, Ciccullo A, Oreni L, Lagi F, Celani L, Colafigli M, De Vito A, Mazzitelli M, Dusina A, Durante M, Montagnani F, Rusconi S, Capetti A, Sterrantino G, D'Ettorre G, Di Giambenedetto S; ODOACRE Study Group. Fabbiani M, et al. Among authors: colafigli m. HIV Med. 2021 Oct;22(9):843-853. doi: 10.1111/hiv.13146. Epub 2021 Jul 27. HIV Med. 2021. PMID: 34318591 Free article.
86 results